1. Home
  2. UUU vs PBM Comparison

UUU vs PBM Comparison

Compare UUU & PBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UUU
    SELLHOLDBUYas of a day ago
  • PBM
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • UUU 1969
  • PBM 1994
  • Country
  • UUU United States
  • PBM Canada
  • Employees
  • UUU N/A
  • PBM N/A
  • Industry
  • UUU Electronic Components
  • PBM
  • Sector
  • UUU Technology
  • PBM
  • Exchange
  • UUU Nasdaq
  • PBM NYSE
  • Market Cap
  • UUU N/A
  • PBM 5.3M
  • IPO Year
  • UUU N/A
  • PBM N/A
  • Fundamental
  • Price
  • UUU $1.78
  • PBM $0.46
  • Analyst Decision
  • UUU
  • PBM
  • Analyst Count
  • UUU 0
  • PBM 0
  • Target Price
  • UUU N/A
  • PBM N/A
  • AVG Volume (30 Days)
  • UUU 6.8K
  • PBM 96.1K
  • Earning Date
  • UUU 02-14-2025
  • PBM 04-15-2025
  • Dividend Yield
  • UUU N/A
  • PBM N/A
  • EPS Growth
  • UUU N/A
  • PBM N/A
  • EPS
  • UUU N/A
  • PBM N/A
  • Revenue
  • UUU $22,168,402.00
  • PBM N/A
  • Revenue This Year
  • UUU N/A
  • PBM N/A
  • Revenue Next Year
  • UUU N/A
  • PBM N/A
  • P/E Ratio
  • UUU N/A
  • PBM N/A
  • Revenue Growth
  • UUU 5.57
  • PBM N/A
  • 52 Week Low
  • UUU $1.11
  • PBM $0.44
  • 52 Week High
  • UUU $2.47
  • PBM $108.00
  • Technical
  • Relative Strength Index (RSI)
  • UUU 40.02
  • PBM 21.53
  • Support Level
  • UUU $1.76
  • PBM $0.58
  • Resistance Level
  • UUU $1.90
  • PBM $0.70
  • Average True Range (ATR)
  • UUU 0.10
  • PBM 0.07
  • MACD
  • UUU 0.01
  • PBM 0.01
  • Stochastic Oscillator
  • UUU 40.00
  • PBM 7.59

Stock Price Comparison Chart: UUU vs PBM

UUU
PBM
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April05101520253035404550556065UUU VS PBM

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use